{"nctId":"NCT01068665","briefTitle":"Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2010-03"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":460,"armGroups":[{"label":"IDeg 200 U/mL OD","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec"]},{"label":"IGlar OD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin glargine"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"insulin glargine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Insulin na√Øve subject (allowed are: previous short term insulin treatment up to 14 days; Treatment during hospitalisation or during gestational diabetes is allowed for periods longer than 14 days)\n* Current treatment: metformin monotherapy or metformin in any combination with an insulin secretagogue (sulfonylurea or glinide), DPP-4 inhibitor, alpha-glucosidase-inhibitors (acarbose) with unchanged dosing for at least 3 months prior to visit 1 with the minimum doses stated: -Metformin: alone or in combination (including fixed combination) 1500 mg daily, or maximum tolerated dose (at least 1000 mg daily) -Insulin secretagogue (sulfonylurea or glinide): minimum half of the daily maximal dose according to local labelling -DPP-4 inhibitor: minimum half of the daily maximal dose according to local labelling - alpha-glucosidase-inhibitors (acarbose): minimum half of the daily maximal dose or maximum tolerated dose\n* HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis\n* Body Mass Index (BMI) maximum 45.0 kg/m\\^2\n* Type 2 diabetes (diagnosed clinically) for at least 6 months\n* Ability and willingness to adhere to the protocol including performance of self monitored plasma glucose (SMPG) profiles according to the protocol\n\nExclusion Criteria:\n\n* Use within the last 3 months prior to Visit 1 of: thiazoledinediones (TZDs), exenatide or liraglutide\n* Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty\n* Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)\n* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements \\[for UK: adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, sterilisation, intrauterine device or intrauterine system, or consistent use of barrier methods\\]\n* Cancer and medical history of cancer hereof (except basal cell skin cancer or squamous cell skin cancer)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycosylated Haemoglobin (HbA1c)","description":"Change from baseline in HbA1c after 26 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.30","spread":"1.04"},{"groupId":"OG001","value":"-1.32","spread":"0.98"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG)","description":"Change from baseline in FPG after 26 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.70","spread":"3.06"},{"groupId":"OG001","value":"-3.38","spread":"2.96"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":228},"commonTop":["Headache","Diarrhoea","Nasopharyngitis","Upper respiratory tract infection"]}}}